Nearly everyone with multiple myeloma relapses. That doesn’t make it easy. A cancer diagnosis is traumatic, especially when the cancer is treatable, but not curable. In multiple myeloma, the disease ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

The approval was supported by data from the ongoing Phase III MajesTEC-3 study.

There’s a newly approved treatment for multiple myeloma that has returned after earlier therapy. The combination of Tecvayli ...

Please provide your email address to receive an email when new articles are posted on . The treatment is approved for heavily pretreated patients. Researchers reported an objective response rate of 70 ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...

Discussion of patient selection criteria, logistical challenges, toxicity management, and when to favor each immunotherapy approach. The final portion of the discussion focuses on future directions in ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...